| Lifeact: a versatile marker to visualize F-actin J Riedl, AH Crevenna, K Kessenbrock, JH Yu, D Neukirchen, M Bista, ... Nature methods 5 (7), 605-607, 2008 | 2344 | 2008 |
| Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53-Hdm2 antagonists A Czarna, B Beck, S Srivastava, G Popowicz, S Wolf, Y Huang, M Bista, ... Angewandte Chemie (International ed. in English) 49 (31), 5352, 2010 | 162 | 2010 |
| Potent and selective inhibitors of MTH1 probe its role in cancer cell survival JG Kettle, H Alwan, M Bista, J Breed, NL Davies, K Eckersley, S Fillery, ... Journal of medicinal chemistry 59 (6), 2346-2361, 2016 | 153 | 2016 |
| Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists D Koes, K Khoury, Y Huang, W Wang, M Bista, GM Popowicz, S Wolf, ... PloS one 7 (3), e32839, 2012 | 122 | 2012 |
| 1, 4‐Thienodiazepine‐2, 5‐diones via MCR (I): synthesis, virtual space and p53‐Mdm2 activity Y Huang, S Wolf, M Bista, L Meireles, C Camacho, TA Holak, A Dömling Chemical biology & drug design 76 (2), 116-129, 2010 | 88 | 2010 |
| Transient protein states in designing inhibitors of the MDM2-p53 interaction M Bista, S Wolf, K Khoury, K Kowalska, Y Huang, E Wrona, M Arciniega, ... Structure 21 (12), 2143-2151, 2013 | 82 | 2013 |
| CRISPR GUARD protects off-target sites from Cas9 nuclease activity using short guide RNAs MA Coelho, E De Braekeleer, M Firth, M Bista, S Lukasiak, ME Cuomo, ... Nature communications 11 (1), 4132, 2020 | 67 | 2020 |
| Mapping the sugar dependency for rational generation of a DNA-RNA hybrid-guided Cas9 endonuclease FO Rueda, M Bista, MD Newton, AU Goeppert, ME Cuomo, E Gordon, ... Nature Communications 8 (1), 1610, 2017 | 67 | 2017 |
| On the mechanism of action of SJ-172550 in inhibiting the interaction of MDM4 and p53 M Bista, D Smithson, A Pecak, G Salinas, K Pustelny, J Min, A Pirog, ... PloS one 7 (6), e37518, 2012 | 63 | 2012 |
| MDMX contains an autoinhibitory sequence element M Bista, M Petrovich, AR Fersht Proceedings of the National Academy of Sciences 110 (44), 17814-17819, 2013 | 61 | 2013 |
| Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper … JW Johannes, A Balazs, D Barratt, M Bista, MD Chuba, S Cosulich, ... Journal of Medicinal Chemistry 64 (19), 14498-14512, 2021 | 56 | 2021 |
| Enzymatic activity of the Staphylococcus aureus SplB serine protease is induced by substrates containing the sequence Trp-Glu-Leu-Gln G Dubin, J Stec-Niemczyk, M Kisielewska, K Pustelny, GM Popowicz, ... Journal of molecular biology 379 (2), 343-356, 2008 | 56 | 2008 |
| Structural and functional characterization of SplA, an exclusively specific protease of Staphylococcus aureus J Stec-Niemczyk, K Pustelny, M Kisielewska, M Bista, KT Boulware, ... Biochemical Journal 419 (3), 555-564, 2009 | 52 | 2009 |
| Domain–domain interactions in full-length p53 and a specific DNA complex probed by methyl NMR spectroscopy M Bista, SM Freund, AR Fersht Proceedings of the National Academy of Sciences 109 (39), 15752-15756, 2012 | 50 | 2012 |
| Positioning high-throughput CETSA in early drug discovery through screening against B-Raf and PARP1 J Shaw, I Dale, P Hemsley, L Leach, N Dekki, JP Orme, V Talbot, ... SLAS DISCOVERY: Advancing the Science of Drug Discovery 24 (2), 121-132, 2019 | 42 | 2019 |
| Robust NMR screening for lead compounds using tryptophan-containing proteins M Bista, K Kowalska, W Janczyk, A Dömling, TA Holak Journal of the American Chemical Society 131 (22), 7500-7501, 2009 | 40 | 2009 |
| MTH1 substrate recognition—an example of specific promiscuity JWM Nissink, M Bista, J Breed, N Carter, K Embrey, J Read, ... PLoS One 11 (3), e0151154, 2016 | 33 | 2016 |
| Quantifying the relationship between inhibition of VEGF receptor 2, drug‐induced blood pressure elevation and hypertension T Collins, K Gray, M Bista, M Skinner, C Hardy, H Wang, JT Mettetal, ... British Journal of Pharmacology 175 (4), 618-630, 2018 | 30 | 2018 |
| Abstract LB-273: A head-to-head comparison of the properties of five clinical PARP inhibitors identifies new insights that can explain both the observed clinical efficacy and … E Leo, J Johannes, G Illuzzi, A Zhang, P Hemsley, MJ Bista, JP Orme, ... Cancer Research 78 (13_Supplement), LB-273-LB-273, 2018 | 26 | 2018 |
| Potent and selective inhibitors of the epidermal growth factor receptor to overcome C797S-mediated resistance MRV Finlay, P Barton, S Bickerton, M Bista, N Colclough, DAE Cross, ... Journal of medicinal chemistry 64 (18), 13704-13718, 2021 | 15 | 2021 |
J. Willem M. Nissinksenior principal scientistVerified email at artios.com
